Why are dendritic cells central to cancer immunotherapy?

Molecular Medicine Today

Volumn 5, Issue 1, 1999, Pages 14-17

  Colaco, Camilo A L S ^a  

^a Quadrant Healthcare   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; REVIEW; TRANSPLANTATION;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0032618982     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01407-5     Document Type: Note

References (36)

1. Lanzavecchia, A. (1993) Identifying strategies for immune intervention, Science 260, 937-944
2. Pardoll, D.M. (1998) Cancer vaccines, Nat. Med. 4, 525-531
3. Young, J.W. and Inaba, K. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted anti-tumour immunity, J. Exp. Med. 183, 7-11
4. Hart, I. and Colaco, C. (1997) Fusion induces tumour rejection, Nature 388, 627-628
5. Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity, Nature 392, 245-252
6. Bakkar, A.B.H. et al. (1995) Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanomaassociated antigen-derived epitopes by dendritic cells in vitro, Cancer Res. 55, 5330-5334
7. Pogador, A. and Gilboa, E. (1995) Bone marrowgenerated dendritic cells pulsed with class-l restricted peptides are potent inducers of cytotoxic T-lymphocytes, J. Exp. Med. 182, 255-260
8. Hsu, F.J. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nat. Med. 2, 52-58
9. Boczkowski, D. et al. (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J. Exp. Med. 184, 465-472
10. Gong, J. et al. (1997) Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells, Nat. Med. 3, 558-561
11. Murphy, G. et al. (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen, Prostate 29, 371-380
12. Nestle, RO. et al. (1998) Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells, Nat. Med. 4, 328-332
13. Gong, J. et al. (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells, Proc. Natl. Acad. Sci. U. S. A. 95, 6279-6283
14. Barratt-Boyes, S.M., Kao, H. and Finn, O.J. (1998) Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo, J. Immunother. 21, 42-48
15. Burnet, F.M. (1970) The concept of immunosurveillance, Prog. Exp. Tumour Res. 13, 1-27
16. Rowse, G.J. et al. (1988) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model, Cancer Res. 58, 315-321
17. Ridge, J.P. et al. (1996) Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells, Science 271, 1723-1726
18. Janeway, C.A. (1992) The immune system evolved to discriminate infectious non-self from non infectious self, Immunol. Today 13, 11-15
19. Ibrahim, M.A.A., Chain, B.M. and Katz, D.R. (1995) The injured cell: the role of the dendritic cell system as a sentinel receptor pathway, Immunol. Today 16, 181-186
20. Matzinger, P. (1994) Tolerance, danger and the extended family, Annu. Rev. Immunol. 12, 991-1045
21. Medzhitov, R. and Janeway, CA. (1997) Innate immunity: impact on the adaptive immune response, Curr. Opin. Immunol. 9, 4-6
22. Fearon, DT. (1997) Seeking wisdom in innate immunity, Nature 388, 323-324
23. Reid, C.D.L. (1998) The biology and clinical applications of dendritic cells, Transf. Med. 8, 77-86
24. Albert, M.L., Sauer, B. and Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class-I restricted CTLs, Nature 392, 86-89
25. Colaco, C. (1998) Towards a unified theory of immunity: antigen capture and the immune response, Cell. Mol. Biol. 6, 883-890
26. Polla, B.S. and Kantengwa, S. (1991) Heat shock proteins and inflammation, Curr. Top. Microbiol. Immunol. 167, 93-125
27. Morimoto, R.I, Kline, M.P, Bimston, D.N. and Cotto, J.J. (1997) The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones, Essays Biochem. 32, 17-29
28. Tamara, Y. et al. (1997) Immunotherapy of tumours with autologous tumour-derived heat-shock protein preparations, Science 278, 117-120
29. Przepiorka, D. and Srivastava, P.K. (1998) Heatshock protein-peptide complexes: potential as cancer immunotherapeutic agents, Mol. Med. Today 4, 478-484
30. Melcher, A. et al. (1998) Tumour immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression, Nat. Med. 4, 581-587
31. Suto, R. and Srivastava, P.K. (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides, Science 269, 1585-1588
32. Colaco, C. (1998) Acquired wisdom in innate immunity, Immunol. Today 19, 50
33. Colaco, C. (1997) Function of fever, J. R. Soc. Med. 90, 587-588
34. Nieland, T.J.F. et al. (1996) Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GPR94, Proc. Natl. Acad. Sci. U. S. A. 93, 6135-6139
35. Suzue, K. et al. (1997) Heat-shock fusion proteins as vehicles for antigen-delivery into the major histocompatability complex class I presentation pathway, Proc. Natl. Acad. Sci. U. S. A. 94, 13146-13151
36. Tomlinson, I.P. and Bodmer, W.F. (1996) The mutation rate and cancer, Proc. Natl. Acad. Sci. U. S. A. 93, 14800-14803